![]() |
|
|
Department of Pharmacology/Toxicology, College of Pharmacy,
University of Texas at Austin (D.A.); and
College of Pharmacy,
Oregon State University (R.J.R.)
Ketoconazole (KT) has been reported to cause hepatotoxicity, which
is probably not mediated through an immunoallergic mechanism. Although
KT is extensively metabolized by hepatic microsomal enzymes, the
nature, route of formation, and toxicity of suspected metabolites are
largely unknown. Recent reports indicate that N-deacetyl
ketoconazole (DAK) is a major initial metabolite in mice, which, like
lipophilic 4-alkylpiperazines, is susceptible to successive oxidative
attacks on the N-1 position producing ring-opened dialdehydes. The rate of formation of DAK from hepatic rat microsomal incubations of KT was
determined by HPLC. The rate of disappearance for KT was almost equal
to the rate of DAK formation: 5.96 and 5.88 µM/hr, respectively.
Also, the potential bioactivation of DAK was evaluated by measuring
substrate activity of DAK with purified pig liver flavin-containing
monooxygenase (FMO) and rat liver microsomes. Activity was measured by
following DAK-dependent oxygen uptake polarographically at 37°C in
pyrophosphate buffer (pH 8.8) containing the glucose-6-phosphate
NADPH-generating system. The KM's of DAK were
34.6 and 77.4 µM for the purified FMO and rat microsomal FMO,
respectively. Lastly, DAK was found to be metabolized by an
NADPH-dependent rat liver microsomal monooxygenases at pH 8.8 to two
metabolites as determined by HPLC. Heat inactivation of rat liver
microsomal FMO abolished the formation of these metabolites from DAK.
SKF-525A and anti-rat NADPH cytochrome P450 reductase did not inhibit
this reaction. These results suggest that deacetylation of KT yields a
major product, DAK, for further metabolism by microsomal monooxygenases
that seem to be FMO-related.
This article has been cited by other articles:
![]() |
H. M. Korashy, A. Shayeganpour, D. R. Brocks, and A. O.S. El-Kadi Induction of Cytochrome P450 1A1 by Ketoconazole and Itraconazole but not Fluconazole in Murine and Human Hepatoma Cell Lines Toxicol. Sci., May 1, 2007; 97(1): 32 - 43. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Donato, N. Jimenez, J. V. Castell, and M. J. Gomez-Lechon FLUORESCENCE-BASED ASSAYS FOR SCREENING NINE CYTOCHROME P450 (P450) ACTIVITIES IN INTACT CELLS EXPRESSING INDIVIDUAL HUMAN P450 ENZYMES Drug Metab. Dispos., July 1, 2004; 32(7): 699 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Miller, G. A. Doss, and R. A. Stearns IDENTIFICATION OF A HYDROXYLAMINE GLUCURONIDE METABOLITE OF AN ORAL HYPOGLYCEMIC AGENT Drug Metab. Dispos., February 1, 2004; 32(2): 178 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Rodriguez and C. L. Miranda Isoform Specificity of N-Deacetyl Ketoconazole by Human and Rabbit Flavin-Containing Monooxygenases Drug Metab. Dispos., September 1, 2000; 28(9): 1083 - 1086. [Abstract] [Full Text] |
||||
![]() |
R. J. Rodriguez, P. J. Proteau, B. L. Marquez, C. L. Hetherington, C. J. Buckholz, and K. L. O'Connell Flavin-Containing Monooxygenase-Mediated Metabolism of N-Deacetyl Ketoconazole by Rat Hepatic Microsomes Drug Metab. Dispos., August 1, 1999; 27(8): 880 - 886. [Abstract] [Full Text] |
||||